Immutep Limited (PRRUF)
| Market Cap | 52.02M -79.9% |
| Revenue (ttm) | 5.28M +62.4% |
| Net Income | -55.97M |
| EPS | -0.04 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,250 |
| Open | 0.0500 |
| Previous Close | 0.0500 |
| Day's Range | 0.0500 - 0.0500 |
| 52-Week Range | 0.0374 - 0.3338 |
| Beta | 2.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Immutep
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II... [Read more]
Financial Performance
In fiscal year 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.
Financial numbers in AUD Financial StatementsNews
Immutep granted new patent for eftilagimod alfa combination
Immutep (IMMP) announced the grant of a new patent entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office, or USPTO. This…
Immutep Post Mautre Overall Survival Data In First-Line NSCLC; Updates On TACTI-004 Analysis
(RTTNews) - Immutep Limited (IMMP), a biotechnology company developing novel immunotherapies announced encouraging results from the investigator-initiated INSIGHT-003 Phase I trial in first-line non-s...
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a ...
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) an...
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advise...
IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of th...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are...
Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors
LOS ANGELES, June 30, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immutep Limited, (“Immutep” or the "Company") (NASDAQ: IMMP) investors of a class action on behalf of investors that bought ...
Robbins LLP Urges IMMP Stockholders to Move for Lead Plaintiff Before the July 6, 2026 Deadline
San Diego, California--(Newsfile Corp. - June 29, 2026) - Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candida...
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)
NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
New York, New York--(Newsfile Corp. - June 17, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed agains...
Immutep upgraded to Buy from Hold at Maxim
Maxim analyst Jason McCarthy upgraded Immutep (IMMP) to Buy from Hold with a $1.50 price target
IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026
Alert: Immutep's 83% Single-Day ADR Collapse Quantifies the Market's Violent Repricing of TACTI-004 Risk That Was Allegedly Known Internally NEW YORK, June 10, 2026 /PRNewswire/ -- Levi & Korsinsky, L...
IMMP Investor Alert - Immutep Limited Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
SAN DIEGO, June 9, 2026 /PRNewswire/ -- Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On May 5, 2026,...
IMMP UPCOMING DEADLINE: Levi & Korsinsky Alerts Immutep Limited Stockholders of Securities Class Action - Contact the Firm
Deadline Alert: IMMP Investors Who Lost Money Between March 2025 and March 2026 Have Until July 6, 2026 to Seek Lead Plaintiff Appointment in Securities Class Action Deadline Alert: IMMP Investors Who...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
New York, New York--(Newsfile Corp. - June 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP)...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
New York, New York--(Newsfile Corp. - June 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP)...
IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit
NEW YORK, June 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP) between March ...
Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On May 5, ...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (“ADRs”) of Immutep Ltd. (NASDAQ: IMMP) between M...
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
New York, New York--(Newsfile Corp. - June 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of Immutep Ltd. (NASDAQ: IMMP)...
IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Key Dates and Disclosure Events Shareholders Need to Know: A Chronological Record of Alleged Misrepresentations Leading to IMMP's 83% Stock Collapse NEW YORK, June 4, 2026 /PRNewswire/ -- SueWallSt en...
Immutep to present positive interim Phase I data for IMP761
Immutep (IMMP) announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European Alliance of Associations for Rheumatology Congress. Initial clinical fi...
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
SYDNEY, AUSTRALIA, June 04, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced it...